MedWatch

FDA approves former Eli Lilly candidate that delays type 1 diabetes onset

US-based Provention Bio has succeed in bringing a former Eli Lilly candidate that delays type 1 diabetes progression to market.

Photo: Hannah Beier/Reuters/Ritzau Scanpix

The US Food and Drug Administration, FDA, has given its regulatory nod to Tzield, which was submitted for review by US-based biotech company Provention Bio and is based on the former Eli Lilly antibody teplizumab.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs